Industry Outlook 2025: Personalizing Precision Medicine and Adopting AI
Pharmaceutical Technology® chatted with Preeya Beczek, managing director and co-founder of Beczek.COM, about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
“I do think there's a number of areas that are going to be trends for 2025 and somewhat continuation from this year,” says Preeya Beczek, managing director and co-founder of Beczek.COM Ltd, a specialist in regulatory affairs and compliance. “There's a real focus on personalizing precision medicine, including cell and gene therapies, and, you know, there's expected to be quite a major trend in this area to really focus on the personalized part of that.”
Additionally, there has been a lot of talk from industry about digital manufacturing and using cloud-based systems to improve efficiency, Beczek continues. And, going hand-in-hand with the data-driven approach is the ability for companies to realize the potential return on investment for their R&D efforts, she adds. “It's really looking at that end to end, moving away from functional silos to looking at the R&D end to end, which I find very exciting, actually, because it can really improve health outcomes and really allow companies to focus on the patient,” Beczek says.
A key trend for 2025 will be artificial intelligence (AI), Beczek specifies. “I think we're just going to have lot more people adopting [Generative AI and] that way of working, in their day-to-day work,” she says. “I think that there's going to be some push to get speed, [in] things like manufacturing timelines, [so] they become shorter.”
Click above to watch the full interview
About the speaker
Preeya Beczek is Director of Beczek Consulting
Preeya Beczek is Managing Director and Co-Founder of Beczek.COM Ltd, a specialist in regulatory affairs and compliance. Preeya has worked in the regulatory affairs and compliance space for over 25 years, focusing on regulatory affairs activities at a strategic and operational level. Prior to her current role, Preeya worked in industry performing a lot of infrastructure and process development to support companies with new systems, initiatives with AI automation, regulatory, information management, system software modernization, and so on.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
